Cargando…

Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report

It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Weichao, Zhu, Minli, Wang, Ruijuan, Tong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/
https://www.ncbi.nlm.nih.gov/pubmed/36206106
http://dx.doi.org/10.1097/CAD.0000000000001402
_version_ 1785019334574211072
author Zhao, Weichao
Zhu, Minli
Wang, Ruijuan
Tong, Zhaohui
author_facet Zhao, Weichao
Zhu, Minli
Wang, Ruijuan
Tong, Zhaohui
author_sort Zhao, Weichao
collection PubMed
description It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance achieving long survival with a median PFS of 46 months. A 52-year-old female diagnosed with stage IV lung adenocarcinoma was tested for no targeted drug benefit in the driver gene. The patient was financially disadvantaged and could not afford and refused immune checkpoint inhibitor drugs but was in the favor of platinum-based double-drug chemotherapy. After six cycles of effective administration of cisplatin in combination with pemetrexed, pemetrexed monotherapy was given for long-term maintenance treatment to date, with a median PFS of 46 months, with a treatment effect close to complete response and tolerable side effects.
format Online
Article
Text
id pubmed-10072206
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100722062023-04-05 Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report Zhao, Weichao Zhu, Minli Wang, Ruijuan Tong, Zhaohui Anticancer Drugs Case Reports It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance achieving long survival with a median PFS of 46 months. A 52-year-old female diagnosed with stage IV lung adenocarcinoma was tested for no targeted drug benefit in the driver gene. The patient was financially disadvantaged and could not afford and refused immune checkpoint inhibitor drugs but was in the favor of platinum-based double-drug chemotherapy. After six cycles of effective administration of cisplatin in combination with pemetrexed, pemetrexed monotherapy was given for long-term maintenance treatment to date, with a median PFS of 46 months, with a treatment effect close to complete response and tolerable side effects. Lippincott Williams & Wilkins 2023-06 2022-10-06 /pmc/articles/PMC10072206/ /pubmed/36206106 http://dx.doi.org/10.1097/CAD.0000000000001402 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Zhao, Weichao
Zhu, Minli
Wang, Ruijuan
Tong, Zhaohui
Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title_full Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title_fullStr Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title_full_unstemmed Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title_short Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
title_sort pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/
https://www.ncbi.nlm.nih.gov/pubmed/36206106
http://dx.doi.org/10.1097/CAD.0000000000001402
work_keys_str_mv AT zhaoweichao pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport
AT zhuminli pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport
AT wangruijuan pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport
AT tongzhaohui pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport